Pharmaceutical composition for treatment and prophylaxis of bacterial infection. RU patent 2520346.
 Flu virus, capable of infecting canidae and its application / 2520081Invention relates to the field of biotechnology and virology. Claimed are isolated strains of the flu virus, capable of infecting canidae and cause respiratory diseases in canidae. Compositions and methods for inducing immune response against the flu virus in canidae are also described. |
| Antibacterial composition, strain of bacteriophage escherichia coli, used for obtaining thereof / 2518303 Invention relates to field of food industry, biotechnology and deals with antibacterial composition and strain of bacteriophage Escherichia coli, used for obtaining said composition. Characterised composition includes filtrate of Escherichia coli phage lysate, obtained with application of strain of bacteriophage Escherichia coli, deposited in collection of museum of microorganisms of Federal Budget Institution of Science "State Research Centre for Applied Microbiology and Biotechnology" of the Federal Service on Customers' Rights Protection and Human Well-being Surveillance (FBIS SRC AMB of Rospotrebnadzor) under number Ph 64, filtrate of Escherichia coli phage lysate, containing coli bacteriophage, filtrate of staphylococcus phage lysate, filtrate of salmonella phage lysate, filtrate of Listeria monocyctogenes phage lysate and target additives in amount 1.0÷95.0 wt % of composition weight. |
| Strain of diploid cells of fetal lung of cattle for reproduction of viruses / 2515915 Strain of diploid cells of fetal lung of cattle is isolated from bovine fetal lung and is deposited in the Specialised Collection of passaged somatic cell cultures of farm and game animals of Russian Collection of vertebrate cell cultures (farm animals of Russian Academy of Agricultural Sciences) at the All-Russian Research Institute of Experimental Veterinary Medicine n.a. Ya.R.Kovalenko (ARIEV) under number 83. The strain is cultivated on medium Igla MEM and GLA of 1:1 with 10% fetal serum of cattle, free from viral, mycoplasmal and bacterial contamination. |
| Associated inactivated emulsion bovine viral diarrhoea, rotavirus and coronavirus infections vaccine / 2515058 Invention refers to veterinary virology and biotechnology, and concerns a bovine viral diarrhoea, rotavirus and coronavirus infections vaccine. The described vaccine contains an active substance and a target additive. As the active substance, the vaccine contains a mixture of an avirulent purified antigen material of the strain NADL-VNIIZZh-DEP of bovine viral diarrhoea of the family Flaviviridae, of the genus Pestivirus, an avirulent purified antigen material of the strain 101 VNIIZZh-DEP of bovine rotavirus of the family Reoviridae, of the genus Rotavirus, and an avirulent purified antigen material of the strain VNIIZZh-DEP of bovine coronavirus of the family Coronaviridae, of the genus Coronaivirus deposited in the Russian National Collection of Microorganism Strains used in veterinary science and animal industry. The strains are taken in the relation of 1:1:1 in the amounts to provide the protective immune activity of each antigen in an animal's body after the target preparation is introduced. |
 Subtype a type 1 iv742 human immunodeficiency viral strain for diagnostic and vaccine preparations / 2513693Invention refers to a subtype A human immunodeficiency viral strain, and can be used in virology, medicine and biotechnology. The presented type 1 IV742 human immunodeficiency viral strain is deposited in the State Collection of Viruses of Federal State Institution Ivanovsky Research Institution of Virology of the Ministry of Healthcare and Social Development of the Russian Federation, No. 1187. The strain possesses a stable reproductive activity. An infectious titre makes 6 lg 50% tissue cytopathic dose. |
 Subtype a type 1 iv710 human immunodeficiency viral strain resistant to antiretroviral preparations for diagnostic and vaccine preparations / 2513692Invention refers to a subtype A human immunodeficiency viral strain, and can be used in virology, medicine and biotechnology. The presented type 1 IV710 human immunodeficiency viral strain is deposited in the State Collection of Viruses of Federal State Institution Ivanovsky Research Institution of Virology of the Ministry of Healthcare and Social Development of the Russian Federation, No. 1188. The strain possesses a stable reproductive activity. An infectious titre makes 3.5-4.0 lg 50% tissue cytopathic dose. |
 Method of quantitative determination of fixed rabies virus "moskva 3253" / 2511440Invention relates to field of biotechnology and deals with method of quantitative determination of fixed rabies virus strain "Moskva 3253". Method includes decontamination and separation of RNA from virus-containing material, carrying out reaction of reverse transcription and polymerase chain reaction with hybridization-fluorescence account of results in "real time" mode with application of specific primers RV5-5'-GTTGGGCACTGAAACTGCTA-3', RV6-5'-GAATCTCCGGGTTCAAGAGT-3' and probe RV7-5'-ROX-AATCCTCCTTGAACTCCATGCGACAGA-BHQ2. Quantitative assessment of virus is determined on the basis of registration of signal of analysed sample fluorescence and its comparison with signal of fluorescence of PCR-standards, which contain different quantities of DNA-targets. Claimed method makes it possible to determine quantitative content of virus in rabies antigen of organ-tissue and culture origin. |
 Influenza virus strain a/hongkong/1/68/162/35 (h3n2) - universal donor of internal genes for reassortants, and reassortant strains a/spb/gk/09 (h1n1) and a/hk/astana/6:2/2010 (h5n1) prepared thereof / 2511431Invention refers to medical biotechnology, and concerns influenza virus strains What is presented is the influenza virus strain A/Hongkong/1/68/162/35 (H3N2) deposited in the State Collection of Viruses of Ivanovskiy Scientific and Research Institution of Virology of Russian Academy of Medical Sciences, No.2442, that is a donor of internal genes for producing reassortant strains and prepared by passaging an agent through chicken embryos. The presented attenuation donor is used to produce the reassortant stains: A/SPb/GK/09 (H1N1) and A/HK/Astana/6:2/2010 (H5N1) deposited in the in the State Collection of Viruses of Ivanovskiy Scientific and Research Institution of Virology of Russian Academy of Medical Sciences, Nos. 2627 and 2626, respectively that inherit high reproductivity (9,5 lg) and an attenuation phenotype (ca) and thermal sensitivity (ts) respectively from the donor. |
 Set of oligodeoxyribonucleotide primers and fluorescently labelled probe for identification of dna of adenoviruses of serotypes 3, 4, 7, 14, 21 by method of hybridisation-fluorescence polymerase chain reaction / 2511043Invention relates to field of biotechnology and deals with set, which includes oligodeoxyribonucleotide primers and fluorescently labelled probe for identification of DNA of adenovirus of serotypes 3, 4, 7, 14, 21 by method of hybridization-fluorescence polymerase chain reaction in real time mode. Claimed primers and probe have the following structure: external primer 5'→3' 5'-AATGTARTTGGGTCTGTTRGGCAT-3' internal primers 5'→3' 5'-CCCWTCGATGMTGCCCC-3' 5'-TCMACGGGYACRAAGCGCA-3' probe 5'→3' ROX-CCTGTCCGGCGATGTGCAT-BHQ2. |
 Strain of xh-18 virus of nuclear polyhedrosis of cotton budworm helicoverpa armigera hbn, used to obtain insecticide preparation / 2511042Strain of virus of nuclear polyhedrosis of cotton budworm Helicoverpa armigera Hbn has high antiviral activity in relation to cotton budworm. It is deposited in the State collection of the Federal Service for Consumer Rights Protection and Human Welfare of causative pathogens of viral infections, rickettsial diseases of Federal Budget Institution of Science of State Science Centre of virology and biotechnology "Vector" under the registration number V-607, and can be used in the production of biological insecticides for agriculture. |
| Salmonella enteritidis var issatschenko 32/3 bacteria strain as means for obtaining biological attractant against mouse-like rodents / 2520161 Bacteria strain Salmonella enteritidis var. Issatschenko 32/3 deposited in the Departmental Collection of Beneficial Microorganisms for Agricultural Purpose of All-Russia Research Institute for Agricultural Microbiology (GNU VNIISHM Rosselkhozakademii) with registration No. RCAM 00149 has expressed pathogenic properties against mouse-like rodents. Efficiency of bioattractant obtained based on Salmonella enteritidis var. Issatschenko 32/3 bacteria strain and grain in grain and vegetable warehouses and green-houses was more than 90% in relation to sewer rat and house mouse. |
 Aeromonas bestiarum bacteria strain - producer of alkaline ribonuclease having antiviral activity / 2520086Invention proposes Aeromonas bestiarum bacteria strain - producer of alkaline ribonuclease having antiviral activity and deposited in a collection of bacteria, bacteriophages and fungi of the Federal Budgetary Scientific Institution "The State Scientific Centre of Virology and Biotechnology "Vector" with registration No. B-1270. Strain has high production rate of alkaline ribonuclease - 921.8 U/ml and activity against A/H5N1 bird and A/Aichi/2/68 (H3N2) human being flu viruses. |
 Completely balanced in nutritional value preparation for babies, probiotic baby food and method of reduction or prevention of inflammation in baby or child / 2520085Invention relates to a preparation for babies for reduction or prevention of inflammation in a baby. The preparation for babies includes a source of protein, providing from 1 to 5 g of protein per 100 kkal of the preparation, a source of fat or lipids, providing from 3 to 7 g of fat or lipids per 100 kkal of the preparation, a source of carbohydrates, providing from 8 to 12 g of carbohydrates per 100 kkal of the preparation, a source of long-chain polyunsaturated fatty acids, including docosahexaenoic acid. The preparation also includes from 1×104 CFU to 1×1010 CFU of Bifidobacterium longum AH1206 NCIMB 41382 per a gram of the preparation. Also claimed are probiotic baby food and a method of reduction or prevention of inflammation in the baby or child with application of the said food. |
 Method of counting oil-oxidising bacteria in sea water / 2520084Invention relates to microbiology and can be used in monitoring environmental-microbiological investigation of the quality of sea water to determine the amount of oil-oxidising microorganisms. The method involves preparing a mineral medium - bases containing NH4NO3, K2HPO4, KH2PO4, MgSO4, CaCl2, FeCl2, a concentrated solution, agar and distilled water in a given ratio, followed by addition of an oil product in a given amount, said product being bunker oil. Seeding sea water on the surface of the culture medium and incubating the seed for 3-4 hours enables to detect colonies of oil-oxidising bacteria. |
 Method of determining sensitivity of microorganisms of salmonella genus to antibacterial agents / 2518372Test kind of microorganisms of the genus Salmonella is incubated, which is taken at a final concentration of approximately 1000 cells/ml, with the test antibacterial agent in the known concentration previously specified for each antibacterial agent, which is optimal for exposure to the specified kind of microorganisms. Incubation is carried out at a temperature of 37°C for 24 hours. The samples are added to the aptamers specific to test species of living microorganisms, fluorescently labelled, at a final concentration of 100 nM. It is incubated for the second time for 20 minutes. The sample is examined using flow cytometry. The level of fluorescence of aptamers is determined by graphs made with a flow cytometer using a program which enables to display a percentage value. The part of bound and un-bound bacteria with the aptamers fluorescently labelled is determined. The amount of the living or non-living organisms in the sample is determined. |
 Strain of rhodococcus sp-destructor of petroleum hydrocarbons / 2518349Strain of Rhodococcus sp. is deposited in the All-Russian Collection of Microorganisms under the registration number Ac-2046 D. The strain exhibits high destructive activity against petroleum hydrocarbons included in the composition of oil slurries, as well as against crude oil and black oil fuel. |
| Two-phase nutritional medium for thin layer cultivation of helicobacter pylori and method of its realisation / 2518304 Invention relates to field of microbiology and can be applied in medicine. Method includes preliminary inoculation of analysed material on Columbia agar with addition of 5% of sheep blood. Thermostatting is performed under microaerophilic conditions in CO2 incubator at 37°C for 3-5 days at higher humidity. Sampling colonies and their re-inoculation on Petri dishes with chocolate agar are performed and thermostatting is carried out under microaerophilic conditions in CO2 incubator at 37°C for 3-5 days at higher humidity. When thermostatting stage is completed Petri dishes with chocolate agar are poured on the top with liquid nutritional medium based on Schaedler broth, enriched with 10% cattle serum with their further thermostatting in CO2 incubator at 37°C for 72 hours. |
 Test-system for differentiating species and biotypes of bacteria of genus yersinia / 2518297Invention relates to field of microbiology and deals with test-system for differentiation of species and biotypes of bacteria of genus Yersinia. Claimed invention consists of a set of nutritional media, which contain substrates and reagents for determination of presence in microorganism of lysine decarboxylase, ornithine decarboxylase, tryptophan deaminase, urease, acetoin production, indole production, meliobiose fermentation, rhamnose fermentation, saccharose fermentation, sorbite fermentation, lipase, xylose fermentation, maltose fermentation, α-methyl-D-glucopyranoside fermentation, salicin fermentation, sorbose fermentation and raffinose fermentation. |
 Anti-obesity preparation, anti-obesity food product or drink, preparation improving tolerance to glucose and food product or drink for improving tolerance to glucose / 2518293Group of inventions relates to field of biotechnology. Strain Bifidobacterium breve MCC 1274 FERM BP-11175 demonstrates low coefficient of conversion of linoleic acid into conjugated linoleic acid. Strain demonstrates coefficient of conversion of linoleic acid into conjugated linoleic acid not higher than 10%. To reduce or prevent obesity or to improve tolerance to glucose said strain is introduced in efficient quantity to subject requiring it. Also claimed are food product and drink, which contain preparation based on said strain. |
| Nutrient medium for submerged cultivation of tularemia microbe / 2518282 Nutrient medium for submerged cultivation of tularemia microbe contains as a base, that provides the content of amino nitrogen in the medium of not less than 0.32%, dry enzymatic hydrolyzate of fibrin obtained from waste of whey-vaccine production, and the components - glucose and calcium pantothenate at a predetermined ratio. |
 Bioregulatory complex possessing tissue-specific regenerative action, method for preparing it and method of treating cataract using it / 2513994Invention refers to pharmaceutical industry, namely a bioregulatory complex possessing regenerative action. The bioregulatory complex possessing regenerative action prepared of gills of post-settlement Atlantic salmon (Salmo salar L.) activated for a prolonged life cycle with symbiotic pearl shell (Margaritifera margaritifera) alevins, containing peptides and oligosaccharides with certain physicochemical characteristics. A method for preparing a bioregulatory complex consisting the fact that the gills are prepared in the Atlantic salmon fished out after the settlement and placed into water or ethanol; the prepared gill extract is filtered; monoatomic aliphatic alcohol is added to the filtrate that is kept to deposit any foreign matters; the deposition is filtered off; the filtrate is evaporated dry, dissolved in water and cleaned in the specific environment. A method of treating early cataract. |
FIELD: biotechnologies.
SUBSTANCE: pharmaceutical composition includes bacteriophages obtained by cultivation on nutritional medium containing glucose, sodium chloride, twice-substituted sodium phosphate, liquid autolysed yeast and clean water in the specified ratio, and dried and having a filler without lyophilisation, in the form of pills with a gastral-resistant coating.
EFFECT: invention allows increasing safety of pharmaceutical composition.
7 ex
The invention relates to biotechnology, in particular to the production of medical biological preparations, and can be used to obtain bacteriophages.
Currently on the territory of the Russian Federation there is a growth of demand for medicines containing bacteriophages. As a consequence is a topical problem of mass and safe industrial production of large quantities of different bacteriophages.
Security issues used biological agents faced by all producers in this industry. Known technologies of production of bacteriophages use various products of animal origin that can lead to allergies and possible contamination by extraneous animal viruses, mycoplasmas and prions contained in animal products.
Closest to the claimed technical substance and the achieved result, chosen as a prototype, nutritive medium is protected by the patent of the Russian Federation 1526225 from 27.05.1995 year. The environment contains as a source of organic nitrogen and physiologically active substances pork peptone, however, the raw material for his serve pork stomachs.
The problem solved by the invention - creation of a secure environment for the cultivation of bacteriophages with high political activity, on the basis of raw materials of animal origin.
The technical result from the use of the invention consists in enhancing the safety of environment and to reduce its cost.
This result is achieved by the fact that the media for cultivation of bacteriophages contains glucose, sodium chloride, sodium phosphate disubstituted, yeast autolysate liquid and purified water in the following ratio of components, mass% on 1 l:
Glucose 0,2-0,3
Sodium chloride 0,25-0,35
Disubstituted sodium phosphate 0,15-0,25.
As hydrolyzed animal raw materials used yeast autolysate liquid, in an amount corresponding 0,12-0,15% amino nitrogen in the environment, or yeast extract dry in the amount of 0,2-0,5% of the total environment.
Water - the rest.
Medium for cultivation of bacteriophages prepared as follows.
The estimated number of hydrolyzed animal raw material is loaded into a reactor fill in water purified and mix. Add sodium hydroxide to pH of 7.7 and 7.8. Boil 40 minutes, making the calculated amount of sodium acetate and sodium phosphate disubstituted, and after 5 min glucose. Then corrects the pH to the original solution of sodium hydroxide.
The cultivation of bacteriophages carried out as follows.
Wash daily agar culture of bacteria sow in the capacity of the proposed environment. The planting density of 4.5 to 5.5·10 6 microbial cells in 1 ml of the medium. At the same time on Wednesday contribute filtrate of fagholizata. Sowing incubated at 36-38 OC for 18-22 hours.
The invention will be described using the following non-limiting examples.
Example 1. Preparation of nutrient media
The nutrient medium for cultivation of bacteriophages prepared as follows. In the reactor add 5 g of yeast extract dry, purified water to 1 liter volume and mix. Add sodium hydroxide to pH of 7.7 and 7.8. Boil 40 min contribute 0.3 g of sodium acetate and 0.2 g sodium phosphate disubstituted, and after 5 min 0.25 grams of glucose. Then corrects the pH to the original solution of sodium hydroxide.
Example 2. Getting staphylococcic bacteriophage
The nutrient medium for cultivation of staphylococcic bacteriophage prepared as in Example 1. As hydrolyzed animal origin used yeast autolysate liquid. In a reactor fill in 100 litres of prepared culture media and produce a crop Staphylococcus based 4,5·10 6 microbial cells per 1 ml of the medium. On Wednesday, at the same time make the filtrate staphylococcic bacteriophage. The cultivation of bacteriophages carried out at a temperature (37 of + / -1)degrees Celsius in the conditions of constant mixing mixer with a speed of 100 rpm and aerating by supply of sterile air in volume (1,5±0,5) l 1 l environment. The cultivation of bacteriophages finish with enlightenment, cultural liquid assessed visually as the turbidity of less than 5 units total ozone amount 42-28-86 P.
Clearing make sterilizing filtration: fagholizata of fermentors by filing a sterile compressed air filter under pressure 0.08 MPa.
The drug staphylococcic bacteriophage characterized lytic activity of the method of Appelman least 10 -4 . The drug free of any animal products.
Example 3. Obtaining, pharmaceutical compositions on the basis of staphylococcic bacteriophage in tablets with gastro-resistant coating
The drug, derived in Example 2, is used to produce pharmaceutical compositions. 100 liters of filtered fagholizata with a title on Appelman not less than 10 -4 served on the ultrafiltration installation using the pump under pressure (0,03±0,01) MPa. Concentrated bacteriophages under pressure (0,015±0,005) MPa is served in cascade microporous membranes. To 1.05 l sterile concentrate fagolizatov with a title on Appelman not less than 10 -7 add 0,006 kg polymer (for example, MCMC).
After the complete dissolution of polymer mixture connect with filler made of calcium carbonate and lactose or mannitol in the ratio of 80:15 parts by weight 1 l of fagholizata add 0,15-0,25 kg napolnitelja. All components of the filling before drying pre-sterilized. After thorough mixing wet mass is spread in a thin layer to the bottom of the cassette, cloth and cover with a sterile freeze-dried in the unit with vacuum from - (7,0-15) PA for 28-32 hours before humidity 3-4%. Mass wipe through a sieve with the size of holes 1 mm, connect with sterile mixture of technological additives from microcrystalline cellulose (MCC), carboxymethyl amylum (KMK), calcium or magnesium stearate ratio 3:1:1 - 4:2:1 based 15-20% of tabletiruemyh of dry mass, carefully mix, pressed into tablets and cover gastro-resistant coating.
1 tablet weighing the 0.09-0.11 g equivalent to 20 ml of liquid bacteriophages Staphylococcus with a titre of at least 10 -4 (Appelman). The activity of phages remained without changes for 2 years at a temperature of 2-10°N Lytic activity of bacteriophage determine when dissolved 5 tablets per 100 ml of culture medium (1 tablet per 20 ml). Prepared 20 experimental-production series of bacteriophage Staphylococcus tablets with acid resistant floors.
Example 4. Getting tablets dysenteric bacteriophage.
Preformed dysenteric bacteriophage received on the techniques described in example 3, without the prior concentration of fagolizatov because activity data bacteriophages exceeds limited title 10 -7 . Cooked 6 experimental series tablet dysenteric bacteriophage. By dissolving 1 tablet weighing the 0.09-0.11 g 20 ml of culture medium titer of bacteriophage was not below 10 -4 .
Example 5. Getting the preformed nextpage (eubacteria).
Sextapes is a mixture of six phages: effluents of fagolizatov cultures staphylococci, streptococci, Escherichia coli, E. coli, Klebsiella, and Proteus. After the information in one volume in equal proportions of the leachate of fagolizatov mentioned cultures mix concentrate 100 times and used for preparation of tablets, as described in example 3. Cooked 16 pilot series of sextopia tablets. By dissolving 1 tablet weighing the 0.09-0.11 g 20 ml of culture medium titles of all phages least 10 -3 and stored at a temperature of 2-10°With at least one year.
Example 6. Receiving the tablets of the bacteriophage Salmonella.
Liquid bacteriophage Salmonella gr. A, b, C, D, E is a purified sterile filtrate of fagolizatov Salmonella: gr. A - Salmonella paratyphi A, gr. In - S. paratyphi In, S.typhimurium, S. heidelberg; gr. C-S. newport, S. choleraesuis, S. oranienburg, S. infantis; gr. D-S. dublin, S. enteritidis; gr. E-S. anatum, S. newlands.
Getting concentrate of bacteriophage:
- Sterile filtrate of fagolizatov with a titre of at least 10 -5 concentrate 50-100 times through ultra-filtration membrane to the title on Appelman 10 -7 . Then concentrates subjected to sterilization filtration through a cascade of microporous membranes with pore size from 0.45 to 0.22 microns. After that concentrated bacteriophages bring in one volume and subsequently used for the preparation of tablets.
- To 100 ml of concentrated bacteriophage add stabilizer (semi-synthetic high-molecular connection - methylcellulose 0.6 g, and a mixture of sugars - sorbitol 20 g, lactose 34 grams). After dissolution of the ingredients stabilized gel-like mass mix with fillers - calcium carbonate 38 g and sodium alginate 7,4 g (providing the frame of the electoral raspadaemosti tablets phages (potential gastric resistance). The ratio of bacteriophage and fillers is 1:1. All fillers before drying pre-sterilized in drying and sterilizing Cabinet twice daily interval within 4 hours at a temperature of 110 degrees C. After thorough mixing received homogeneous pasty mass is spread in a thin layer to the bottom of the cassette, cloth and cover with a sterile vacuum or freeze-dried in the freeze-up to the humidity of 3-4%. Technological loss during drying and grinding are compensated by the dry residue of bacteriophage, so the actual output of semi-finished product meets the regulatory total loading of components. Dry weight wipe through a sieve with the size of holes 1 mm, connect with sterile mass-purpose additives (auxiliary sliding substances - 1.0 g magnesium stearate), mix thoroughly and pressed into tablets weight of 0.2 g, the equivalent volume of 20 ml commercial product.
Example 7. Getting the preformed Nextpage (Eubacteria polyvalent).
Thus, we get a bacteriophage preparations are characterized by high purity by reducing admixtures of animal origin, which has a positive effect on the human body, at the time of their admission, by reducing the risk of allergic reactions.
The pharmaceutical composition for the treatment and prevention of bacterial infection that contains bacteriophages, dried with fillers without lyophilization, in the form of tablets with gastro-resistant coating, characterized in that it contains bacteriophages obtained by culture on a nutrient medium, containing glucose, sodium chloride, sodium phosphate disubstituted, yeast autolysate liquid and purified water in the following ratio of components, mass% on 1 l:
Glucose 0,2-0,3Sodium chloride
0,25-0,35
Disubstituted sodium phosphate
0,15-0,25
Yeast autolysate liquid
0,2-0,5 Water else